TABLE 1.
Association of TMEM60 expression is with the clinicopathological characteristics of patients with glioma.
| Clinical Features | Patient number | TMEM60 expression | Univariate analysis | |||||
|---|---|---|---|---|---|---|---|---|
| High | Low | χ2 | P | HR | 95%CI | p-value | ||
| Age | 0.14 | 0.71 | 2.50 | (1.07–5.79) | 0.03 | |||
| <48 | 13.00 | 6.00 | 7.00 | |||||
| ≥48 | 17.00 | 9.00 | 8.00 | |||||
| Gender | 0.13 | 0.72 | 1.47 | (.69–3.14) | 0.32 | |||
| Female | 15.00 | 8.00 | 7.00 | |||||
| Male | 15.00 | 7.00 | 8.00 | |||||
| WHO grade | 8.17 | 0.02 | 1.85 | (1.09–3.13) | 0.02 | |||
| Ⅱ | 11.00 | 2.00 | 9.00 | |||||
| Ⅲ | 9.00 | 5.00 | 4.00 | |||||
| Ⅳ | 10.00 | 8.00 | 2.00 | |||||
| KPS score | 2.40 | 0.12 | 1.88 | (.87–4.08) | 0.11 | |||
| <80 | 10.00 | 7.00 | 3.00 | |||||
| ≥80 | 20.00 | 8.00 | 12.00 | |||||
| Tumor location | 0.69 | 0.87 | 1.29 | (.93–1.79) | 0.12 | |||
| Occipital lobe | 2.00 | 1.00 | 1.00 | |||||
| Parietal lobe | 3.00 | 2.00 | 1.00 | |||||
| Temporal lobe | 9.00 | 5.00 | 4.00 | |||||
| Frontal lobe | 16.00 | 7.00 | 9.00 | |||||
| Tumor volume(cm3) | 0.54 | 0.46 | 1.27 | (.59–2.75) | 0.54 | |||
| <32 | 16.00 | 7.00 | 9.00 | |||||
| ≥32 | 14.00 | 8.00 | 6.00 | |||||
| Postsurgical radiotherapy | 0.14 | 0.70 | 0.72 | (.33–1.59) | 0.42 | |||
| Yes | 19.00 | 9.00 | 10.00 | |||||
| No | 11.00 | 6.00 | 5.00 | |||||
| Postsurgical TMZ therapy | 0.54 | 0.46 | 0.64 | (.29–1.44) | 0.28 | |||
| Yes | 14.00 | 8.00 | 6.00 | |||||
| No | 16.00 | 7.00 | 9.00 | |||||
| TMEM60 | 30.00 | 15.00 | 15.00 | - | - | 1.57 | (1.01–2.43) | 0.04 |
Values in bold indicate statistical significance (p < .05). KPS, score, Karnofsky performance score; HR, hazard ratio; CI, confidence interval.